Click Therapeutics Inc featured prominently this week with new clinical data and strategic messaging that underscore its ambitions in digital therapeutics. The company highlighted a peer-reviewed publication in npj Digital Medicine covering two Phase III trials of CT-132, its FDA-authorized prescription digital therapeutic for episodic migraine prevention.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The integrated post-hoc analysis of the ReMMi-D and ReMMiD-C studies, spanning 678 patients, showed statistically significant reductions in monthly migraine days. It also reported improvements in migraine-related disability and quality-of-life measures, with a stated p-value of 0.003 and no device-related adverse events.
Benefits were observed when CT-132 was used alongside a broad range of standard migraine therapies, including CGRP inhibitors, reinforcing its positioning as an adjunctive option rather than a replacement. This compatibility may help ease adoption among clinicians and support payer arguments that the software can be layered onto existing treatment regimens.
Beyond CT-132, Click continued to advance its broader digital strategy around Over-the-Counter Digital Therapeutics, or ODTx. CEO David Benshoof Klein is slated to present this concept at the US Pharma and Biotech Summit hosted by FT Live with Endpoints News, framing ODTx as a bridge between consumer wellness apps and medical-grade software.
The company describes ODTx as converting passive biometric data from wearables and apps into actionable treatment interventions, positioning the category as a potential “missing link” in digital health. This approach aligns with industry trends toward continuous monitoring and personalized care, and could open more scalable, consumer-facing revenue channels if accepted by payers and platforms.
In parallel, Click is promoting its Prescription Drug Use-Related Software, or PDURS, framework as a way for pharma partners to create Software-Enhanced Drugs. By embedding its software into FDA-authorized drug labels and commercialization workflows, the company aims to extend product lifecycles and bolster outcomes in a market facing patent cliffs and payer scrutiny.
Collectively, the week’s developments strengthened Click Therapeutics’ clinical and strategic narrative, combining late-stage efficacy data in migraine with a multi-pronged platform vision in PDURS and ODTx. These moves reinforce the company’s positioning as an enabling partner at the intersection of pharmaceuticals and digital health, setting the stage for potential future growth as evidence and partnerships evolve.